The demand for Connected Drug Delivery Devices is growing at an immense pace owing to the increasing geriatric population and rising prevalence of chronic diseases. In addition, the superior outcomes of the Connected Drug Delivery Devices such as setting alarms and alerts for the dose administration, continuous examination of the dose regimen and disease condition, and others to improve patient treatment outcomes will lead to an increased demand for the device. Moreover, the rising awareness about adherence to prescribed therapies and self-administration of drugs, and innovation in product development among others are also contributing to the overall growth of the Connected Drug Delivery Devices market. The leading MedTech and HealthTech giants working in the Connected Drug Delivery Devices Market include Findair Sp. z o. o., Adherium, Propeller Health., West Pharmaceutical Services, Inc., BIOCORP, Phillips-Medisize, Merck KGaA, Novo Nordisk A/S, Medtronic, Tandem Diabetes Care, Inc., Ypsomed, Teva Pharmaceutical Industries Ltd., Elcam Medical, Cohero Health, Inc., BD., and others.
DelveInsight’s “Connected Drug Delivery Devices Market Insight, Competitive Landscape, and Market Forecast 2028” research report provides the current and forecasted Connected Drug Delivery Devices market size, share, and trends analysis for the next five years. Moreover, it highlights the ongoing innovations in the segment, major market drivers & barriers, key competitors, and emerging devices in the domain.
Connected Drug Delivery Devices Market: Overview
Connected Drug Delivery Devices are medical devices that combine drug delivery mechanisms with connectivity features, allowing for enhanced monitoring, control, and patient engagement in the management of medication administration. These devices typically consist of a drug delivery system, such as an inhaler, insulin pen, or autoinjector, which is integrated with electronic components and wireless connectivity capabilities. The main purpose of Connected Drug Delivery Devices is to improve medication adherence, patient outcomes, and disease management. They offer several features and benefits such as connectivity, medication reminders, dose tracking and monitoring, real-time feedback and guidance, data analytics and insights, remote monitoring and support, patient engagement and education, and several others.
Connected Drug Delivery Devices are used in various therapeutic areas, including respiratory diseases (such as asthma and chronic obstructive pulmonary disease), diabetes, multiple sclerosis, rheumatoid arthritis, and more. They aim to improve medication adherence, reduce hospitalizations, and empower patients to actively participate in their healthcare management.
To provide a better understanding of the market dynamics, DelveInsight’s “Connected Drug Delivery Devices Market” report provides an in-depth assessment of the market by product types such as connected sensors (connected inhaler sensors and connectable injection sensors) and integrated connected devices (connected inhaler devices and connected injection devices), by technology (Bluetooth, near-field communication (NFC), and others), and by end-user (healthcare providers and home care).
As per the estimate, in the product segment of the Connected Drug Delivery Devices market, the Bluetooth category is expected to amass significant revenue share in the upcoming years, owing to the higher utilization of Bluetooth technology due to its higher compatibility with other drug delivery devices and ease of use. The increasing strategic activities by the key players will also drive the market of Bluetooth-Connected Drug Delivery Devices Market growth in the coming years. Overall, the anticipated growth of Bluetooth-Connected integrated drug delivery devices will help to fuel the expansion of the Connected Drug Delivery Devices market in the coming years.
Connected Drug Delivery Devices Market Analysis
The increasing geriatric population and rising prevalence of chronic diseases like diabetes, among others, are key factors in the growing demand for Connected Drug Delivery Devices. As per the estimate, in 2021, approximately 537 million adults (20–79 years) were living with diabetes, globally. Also, the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. The increasing patient engagement and connectivity due to the rising penetration of the Internet of Things (IoT) in the medical devices sector are likely to bode well for the market growth during the forecast period. The incorporation of the Internet with medical devices will propel the demand for Connected Drug Delivery Devices, as these devices are connected to the Internet for their smooth flow.
The growing demand to increase patient medication adherence is another significant driver propelling market expansion. People will be able to manage their medication more effectively by lowering the frequency of trips to clinics and hospitals as more people adopt connected drug-delivery devices. The right dosage and administration are aided by connected devices, leading to a successful treatment without the need for expensive interventions. These systems also feature adherence trackers and reminders, which make it simpler for patients to follow their prescribed prescription schedule. Moreover, various commercial and strategic activities such as collaboration, acquisitions, and partnerships, among others are also propelling the market growth.
Despite several favorable factors, some of the key aspects such as security and data breaching concerns, and environmental concerns for the disposal of electronic waste, among others are expected to hamper the Connected Drug Delivery Devices market growth.
Interested to know more about the ongoing developments in the market? Visit to get an in-depth insight @ Connected Drug Delivery Devices Types and Emerging Products
Connected Drug Delivery Devices – Global Market Assessment and Forecast
In terms of geographical market share distribution, North America is anticipated to hold the greatest market share for Connected Drug Delivery Devices in the upcoming years. The North American Connected Drug Delivery Devices market is being driven by key factors like the rising prevalence of chronic diseases (such as respiratory illnesses, hypertension, and diabetes among others), the aging population vulnerable to chronic diseases, and rising government initiatives regarding disease awareness of self-administration of drugs using Connected Drug Delivery Devices. Additionally, a high level of disposable income, an advanced healthcare system, and high levels of awareness will contribute to the market expansion. Along with the aforementioned elements, the rising number of product launches and approvals is also expected to increase regional product demand. Moreover, the region is expected to witness a high number of clinical and commercial development activities in the upcoming years, which will favorably drive the overall market growth in the region.
Interested in knowing how the Connected Drug Delivery Devices market will grow by 2028? Click to get a snapshot @ Connected Drug Delivery Devices Market Trends and Developments
Connected Drug Delivery Devices Market – Key Developments and Breakthroughs
Over the years, the Connected Drug Delivery Devices market has evolved significantly, owing to the active participation of companies and intense technological advancements in the domain. Similarly, several clinical, commercial, and regulatory developments have also been registered in the domain. Some of the major advancements in the Connected Drug Delivery Devices market in recent years include –
- In October 2022, ALCOR and Merck KGaA agreed on the development and supply of a specific version of Mallya device as an accessory for one of Merck KGaA, Darmstadt, Germany’s drug delivery devices. Mallya is a Bluetooth-enabled clip-on device for pen injectors that collects the dose and time of each injection and transfers information in real-time to companion software.
- In July 2022, Adherium Limited announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market an application connecting GlaxoSmithKline’s (GSK) Ellipta® inhaler users with Adherium’s new, next-generation Hailie sensor with physiological parameters for monitoring Asthma and COPD medication use.
- In February 2022, Aptar Pharma announced the launch of HeroTracker Sense, a breakthrough digital respiratory healthcare system that transforms a typically metered dose inhaler into a smart linked healthcare system.
- In May 2021, Eli Lilly and Company collaborated with 4 companies- Glooko Inc., DexCom, Inc., Roche, and myDiabby Healthcare- to advance connected solutions for diabetics in markets outside the US. The diabetes management platforms being offered by the companies are expected to be compatible with Lilly’s Tempo Pen (available in various markets across the globe) and Tempo Smart Button (in late-stage development) to support diabetes patients.
- In June 2020, Propeller Health entered into a partnership with Novartis. By entering into the partnership, Propeller’s digital health platform will co-package Novartis’ Enerzair Breezhaler to effectively treat patients suffering from asthma.
- In July 2020, Novartis received EC approval for Enerzair® Breezhaler which is used as a maintenance treatment of asthma in adult patients. The inhaler is connected to the app using Bluetooth technology.
Learn more about major clinical and commercial development in the Connected Drug Delivery Devices Market @ Connected Drug Delivery Devices Market – Clinical and Commercial Development Activities
Key Companies in the Connected Drug Delivery Devices Market
Globally, some of the leading Connected Drug Delivery Devices companies actively working in the market include Findair Sp. z o. o., Adherium, Propeller Health., West Pharmaceutical Services, Inc., BIOCORP, Phillips-Medisize, Merck KGaA, Novo Nordisk A/S, Medtronic, Tandem Diabetes Care, Inc., Ypsomed, Teva Pharmaceutical Industries Ltd., Elcam Medical, Cohero Health, Inc., BD., and others. Owing to the rising demand and favorable growth opportunities for revenue generation, several new players are anticipated to enter the market, thereby leading to high competitiveness in the domain.
Learn how new players’ entries will transform the Connected Drug Delivery Devices market dynamics in the coming years @ Connected Drug Delivery Devices Competitive Landscape
Scope of the Connected Drug Delivery Devices Market Report:
- Study Period – 2020-2028
- Geography Covered – North America, Europe, Asia-Pacific, and Rest of the World
- Connected Drug Delivery Devices Market Assessment –
-
-
- By Product – Connected Sensors [Connected Inhaler Sensors and Connectable Injection Sensors] and Integrated Connected Devices [Connected Inhaler Devices and Connected Injection Devices
- By Technology – Bluetooth, Near-Field Communication (NFC), and others
- By End-User – Healthcare Providers and Homecare
-
- Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s Views
Table of Content
| 1 | Report Introduction |
| 2 | Executive Summary |
| 3 | Regulatory and Patent Analysis in the Connected Drug Delivery Devices Market |
| 4 | Connected Drug Delivery Devices Market Key Factors Analysis |
| 5 | Connected Drug Delivery Devices Porter’s Five Forces Analysis |
| 6 | COVID-19 Impact Analysis on the Connected Drug Delivery Devices Market |
| 7 | Connected Drug Delivery Devices Market Layout |
| 8 | Connected Drug Delivery Devices Companies Share Analysis – Top 3–5 Companies |
| 9 | Connected Drug Delivery Devices Companies and Major Product Profiles |
| 10 | Project Approach |
| 11 | KOL Views on Connected Drug Delivery Devices Market |
| 12 | DelveInsight Capabilities |
| 13 | Disclaimer |
| 14 | About DelveInsight |
Reach out to us to get a more detailed overview of the market @ Connected Drug Delivery Devices Market Insights and Competitive Landscape
Other Trending Healthcare Reports by DelveInsight:
3d Cardiac Mapping System Market | Acute Pulmonary Embolism Market | Aortic Stenosis Market | Bile Duct Neoplasm Market | Carcinoid Tumor Market | Cluster Headache Market | Condyloma Market | Familial Primary Pulmonary Hypertension Market | Fibrocystic Breast Condition Market | Meningioma Market | Progressive Multifocal Leukoencephalopathy Market | Rhino Conjunctivitis Market | Ventilator Market |Intracranial Pressure Monitoring Devices Market | Hemodynamic Monitoring Systems Market | Automated External Defibrillators Market | Neurostimulation Devices Market | Neuroprosthetics Market | Eczema Market | Foot And Ankle Devices Market | Neuroblastoma Market | Pharmaceutical Consulting Companies | Allergic Conjunctivitis Market | Biotech Consulting | Cervical Intraepithelial Neoplasia Market | Osteoarthritis Market | Pruritus Market | Capnography Device Market | Image Guided Surgery Devices Market | Opioid Induced Constipation Market | Alzheimer Disease Market | Angioedema Market | Neurovascular Devices Market | Actinic Keratosis Market | Acute Coronary Syndrome Market | Blood Gas And Electrolyte Analyzers Market
Leverage the potential of consulting services to overcome the competition in the highly evolving and dynamic healthcare market with Healthcare Regulatory Analysis and Merger and Acquisitions in Healthcare Industry
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact Us
Shruti Thakur
Manager (Marketing & Branding)
info@delveinsight.com
+1(919)321-6187.